Heartening to see such insight here on Twitter. Thank you David standing up for the people who do so much good yet who are among the most hated in America. It’s a paradox that needs resolving. The problems can be fixed; let’s not lose sight of the net good… ie this!

We can't ask everyone to learn all the science on their own. We can't even ask every single doctors to; there's not enough time in the day. This is why we create institutions like the CDC to process data and share the bottom line. Gotta trust someone. Just don't trust measles.

Here's Q&A with lots of data on vaccines. It's written plainly because we wrote it for our own families and friends. No, we do not yet have a Tylenol section... never saw that left turn coming. There are data on that, too.

Going natural sounds nice until you consider how ugly and cruel nature can be. It's a battle out there. Let's not let the pathogens get the better of us. Detailed data below.

Nima is only in early access now. But soon will be relaunching. Our goal is for employer plans & all insurance to cover this so the 1% of population with celiac can eat with less fear of gluten cross-contamination. Cause a kitchen’s mistake means pain.

Shout out to Geddy’s in bar harbor. When they say they can do gluten free, they really do. Tested two dishes with my NIMA gluten tester (RA Capital got production on track) and they passed! Two family members with #celiac can eat safely. @thisisnimanow

Resolving the Massachusetts Paradox The biopharmaceutical industry’s crisis communication plan begins at home https://t.co/Yjm69Vi0nS @PeterKolchinsky

Some think DTC drug ads should be banned as in other countries. Europe bans ads b/c they don't want to spend money on novel medicines (until they go generic), so they keep their citizens in the dark. Don't fall for anti-pharma misinformation. #MAParadox @NPLB_org

This is the message I hope all Americans angry at the pharma industry will hear from all of us working on fighting disease (ie what we should be angry at). New medicines can be affordable with proper insurance.

The roadmap to resolving the Massachusetts Paradox. There’s a role here for every biotech company. You have a great story to contribute.

Gotta admit this is maddening. How could we have let things get so bad? I propose a solution for how to turn things around. Link to roadmap in next post. @NPLB_org

It's a long piece because it offers an action plan. And because it's comprehensive, you can just use AI to query the article itself. We provide a link at the top to start that AI discussion. If you're compelled by the call to action, sign up to get involved (link in article).

Everyone in biopharma has grappled w/ the paradox of doing what we know is vital work that can transform/save lives while seeing our industy rank among the public's most hated. Here's what we can do to finally, in earnest, try to resolve it and win fans.

This is illogical keyword salad. For example, the markups are what PBMs apply. Whatever LLM powers this ai (grok likely) needs a tune up on healthcare before it can properly snark.

We made this year's @FierceHealth 50 list! What we're pushing for is not only possible, but crucial. We don't have to settle for bad policies like MFN and the pill penalty. We CAN make meds more affordable AND protect innovation. Learn about our work:

For more on vaccines and pathogens, our team prepared a pretty clear Q&A.

If vaccines are all about trust and facts, that maybe we need to reframe. Measles is deadly. one doesn’t need to know everything about vaccines if one knows even a little about the pathogen.

Abbvie has completed its acquisition of Capstan Therapeutics. Today on Rapport, some of the RA Capital team on that journey from the beginning share the story of the ideas, the science, the pivots, and the people behind Capstan.

How to measure a drug candidate's value, particularly when there are few if any comps? A case study on modeling value, today on Rapport

Hear hear! NPLB's Peter Rubin: “[People in biopharma] are passionate about being entrepreneurial in the sense of building something that’s going to be good for society. There’s a reason why they’re doing this versus building apps for Netflix or whatever.”

Maria Yemane, a visiting student at Harvard Med with a neuroscience + drug discovery background, joined the NPLB Biotech Fellowship to explore biotech investing + real-world healthcare solutions. 💬 “A highlight was discussing these topics with @PeterKolchinsky, which gave me